BioTuesdays

Tag - Stifel

Atara logo
Markets

Stifel cuts Atara Biotherapeutics to hold; PT to $5

Stifel downgraded Atara Biotherapeutics (NASDAQ:ATRA) to “hold” from “buy” and lowered its price target to $5 from $16, following the company’s interim Phase 2 analysis with ATA188 for the treatment of multiple...

July 13, 2022
HilleVax
Markets

Analysts start HilleVax at buy, outperform

Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...

May 24, 2022
IDEAYA Biosciences Logo
Markets

Stifel ups IDEAYA Biosciences to buy; PT cut to $20

Stifel upgraded IDEAYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” but cut its price target to $20 from $27, saying the risk/reward around the company’s IDE397 drug candidate is favorable with the stock in the mid-to...

March 10, 2022
Markets

Stifel starts Vigil Neuroscience at buy; PT $24

Stifel initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “buy” rating and $24 price target. The stock closed at $12.90 on Jan. 31. Vigil is focused on precision medicine approaches to treat dementia, with a...

February 1, 2022
ViewRay Logo
Markets

Stifel starts ViewRay at buy; PT $7

Stifel initiated coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and price target of $7, reflecting a multiple of 8.3 times estimated 2023 revenue of $130-million. The stock closed at $4.46 on Jan. 24. “We see...

January 25, 2022
Apollo Endosurgery
Markets

Stifel starts Apollo Endosurgery at buy; PT $12

Stifel launched coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and $12 price target. The stock closed at $8.59 on Dec. 8. Apollo Endosurgery is a medical technology company focused on design...

December 9, 2021
Bolt-Biotherapeutics
Markets

Stifel cuts Bolt Biotherapeutics PT to $19 from $34

Stifel reduced its price target for Bolt Biotherapeutics (NASDAQ:BOLT) to $19 from $34, but maintained its “buy” rating, after the company presented interim clinical data from an ongoing Phase 1/2 study of BDC-1001, its...

December 6, 2021